All In Biotech

Drug Trial Radar · NCT06813781

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Dec 19, 2024

Primary completion

Oct 2, 2025

Study completion Oct 2, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Fortrea Clinical Research Unit Inc.
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • AZD5004Drug

    Dose 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCinfTime frame: Day 1 to Day 6
  2. AUClastTime frame: Day 1 to Day 6
  3. CmaxTime frame: Day 1 to Day 6

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Lake Forest, California

  • Research Site

    Rialto, California

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.